Literature DB >> 24640516

Predicting outcome after Fontan palliation: a single-centre experience, using simple clinical variables.

Katrien De Vadder, Alexander Van De Bruaene, Marc Gewillig, Bart Meyns, Els Troost, Werner Budts.   

Abstract

BACKGROUND: The Fontan procedure has become the procedure of choice for patients with one functional ventricle. Although perioperative mortality has decreased, late failure of the Fontan circulation remains a major concern. We aimed at (i) describing Fontan patient characteristics and (ii) identifying simple risk factors for outcome.
METHODS: Seventy-three patients (median age 23 y (IQR 19-29 y), 60.3% male) were selected from the database of congenital heart defects. Followup data were collected. The primary end point was composed by death, resuscitation, or heart transplantation.
RESULTS: The most frequently occurring defect was tricuspid atresia (41.1%). Twenty-five (34.2%) and 48 (65.8%) patients received an intra- and extracardiac conduit, respectively. Ten patients reached the primary end point (13.7%) after a median follow-up time of 16 years (IQR 14-19 y). NYHA classification (OR 63.0; 95% Cl 6.7-592.4; P < or =0.001), atrioventricular-valve regurgitation (OR 10.6; 95% Cl: 1.2-94.1; P = 0.034), ventricular function (OR 4.8; 95% Cl 1.7-13.7; P = 0.003), oxygen saturation (OR 0.7; 95% Cl 0.1-1.0; P = 0.002) and the presence (OR 8.6; 95% Cl 1.6-45.2; P = 0.011) or history of supraventricular arrhythmia (OR 6.7; 95% CI: 1.3-35.0; P = 0.025), all parameters gathered at the latest follow-up, were associated with outcome. An association was also found with the presence of an intracardiac conduit (OR 5.8; 95% Cl 1.4-25.1; P = 0.018), higher age at Fontan procedure (OR 1.2; 95% Cl 1.0-1.3; P = 0.007) and male gender (OR 0.2; 95% Cl 0.1-1.0; P = 0.047).
CONCLUSIONS: Complications were not uncommon later after Fontan surgery. Several demographic and procedure-related data were associated with adverse outcome. Interestingly, the strongest correlation was found with clinical and basic echocardiographic characteristics at the latest follow-up.

Entities:  

Mesh:

Year:  2014        PMID: 24640516     DOI: 10.1080/ac.69.1.3011339

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  6 in total

1.  Assessing Single Ventricle Function in the Fontan Circulation using Wave Intensity Analysis.

Authors:  John Valdovinos; Nicolas Eng; Matthew Russell; Samuel Zahn; Daniel S Levi
Journal:  Pediatr Cardiol       Date:  2021-01-29       Impact factor: 1.655

Review 2.  Evaluating the Longevity of the Fontan Pathway.

Authors:  John M Kelly; Gabriel J M Mirhaidari; Yu-Chun Chang; Toshiharu Shinoka; Christopher K Breuer; Andrew R Yates; Kan N Hor
Journal:  Pediatr Cardiol       Date:  2020-11-08       Impact factor: 1.655

3.  Differentiation of Impaired From Preserved Hemodynamics in Patients With Fontan Circulation Using Real-time Phase-velocity Cardiovascular Magnetic Resonance.

Authors:  Hermann Körperich; Katja Müller; Peter Barth; Jürgen Gieseke; Nikolaus Haas; Ingram Schulze-Neick; Wolfgang Burchert; Deniz Kececioglu; Kai T Laser
Journal:  J Thorac Imaging       Date:  2017-05       Impact factor: 3.000

Review 4.  Pulmonary hypertension in congenital heart disease.

Authors:  Emma Pascall; Robert Mr Tulloh
Journal:  Future Cardiol       Date:  2018-05-24

5.  A Multimodal Score Accurately Classifies Fontan Failure and Late Mortality in Adult Fontan Patients.

Authors:  Peter Kramer; Anastasia Schleiger; Marie Schafstedde; Friederike Danne; Johannes Nordmeyer; Felix Berger; Stanislav Ovroutski
Journal:  Front Cardiovasc Med       Date:  2022-03-10

Review 6.  Failures of the Fontan System in Univentricular Hearts and Mortality Risk in Heart Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Horacio Márquez-González; Jose Gustavo Hernández-Vásquez; Montserrat Del Valle-Lom; Lucelli Yáñez-Gutiérrez; Miguel Klünder-Klünder; Eduardo Almeida-Gutiérrez; Solange Gabriela Koretzky
Journal:  Life (Basel)       Date:  2021-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.